imlifidase
Recombinant proteinexperimental
Imlifidase, brand name Idefirix, is a medication for the desensitization of highly sensitized adults needing kidney transplantation, but unlikely to receive a compatible transplant. — Wikipedia
Clinical trial activity
24 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
20
Phase 3
4
Phase 4
0
Earliest trial started Feb 1, 2013 (NCT01802697)
Timeline
Indications
Studied for
- Anti-Glomerular Basement Membrane Disease · Phase 3
- Autoimmune Diseases · Phase 3
- Bile Duct Neoplasms · Phase 2
- Cholangiocarcinoma · Phase 2
- Crigler-Najjar Syndrome · Phase 2
- Guillain-Barre Syndrome · Phase 2
- Healthy Volunteers · Phase 1
- Kidney Diseases · Phase 1/Phase 2
- Kidney Failure, Chronic · Phase 2
- Kidney Transplantation · Phase 3
- Mesothelioma · Phase 2
- Muscular Dystrophy, Duchenne · Phase 1
- Neoplasms · Phase 1/Phase 2
- Purpura, Thrombotic Thrombocytopenic · Phase 1/Phase 2
- Renal Insufficiency, Chronic · Phase 2
Mechanism of action
- AntibodiesHYDROLYTIC ENZYME
Antibodies hydrolytic enzyme
Reduces the level of donor-specific antibodies thus enabling transplantation.
- Fibroblast growth factor receptor 3INHIBITOR
Fibroblast growth factor receptor 3 inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
Fibroblast growth factor receptor 2 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
Fibroblast growth factor receptor 1 inhibitor
- Streptococcus pyogenesINHIBITOR
Streptococcus pyogenes inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaImlifidase ↗
- ChEMBLCHEMBL4650297 ↗
- ChEMBLCHEMBL4297981 ↗
- WikipediaIdes ↗
Also known as
- hmed-ides
- hmpl-453
- ides
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06461546 | Phase 2 | Nov 30, 2024 | Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona |
| NCT06518005 | Phase 2 | Oct 15, 2024 | Genethon, HansaBioMed |
| NCT06241950 | Phase 1 | Jan 29, 2024 | HansaBioMed, Sarepta Therapeutics |
| NCT05937750 | Phase 3 | Jul 3, 2023 | HansaBioMed |
| NCT05753930 | Phase 2 | Jun 2, 2023 | HansaBioMed |
| NCT05930119 | Phase 1 | Mar 17, 2023 | University of Washington |
| NCT05679401 | Phase 3 | Dec 22, 2022 | HansaBioMed |
| NCT05369975 | Phase 3 | Apr 19, 2022 | HansaBioMed |
| NCT05173142 | Phase 1/Phase 2 (Phase 2) | Jan 22, 2022 | Hutchison MediPharma |
| NCT05049850 | Phase 2 | Oct 31, 2021 | HansaBioMed |
| NCT04935177 | Phase 3 | Oct 14, 2021 | HansaBioMed |
| NCT04353375 | Phase 2 | May 30, 2020 | Hutchison MediPharma, People's Liberation Army of China |
| NCT04290325 | Phase 2 | Mar 30, 2020 | Hutchison MediPharma, Jiao Tong University |
| NCT03943589 | Phase 2 | Jun 6, 2019 | HansaBioMed |
| NCT03897205 | Phase 2 | Apr 30, 2019 | HansaBioMed |
| NCT03160833 | Phase 1/Phase 2 (Phase 2) | May 23, 2017 | Hutchison MediPharma |
| NCT03157037 | Phase 2 | Mar 1, 2017 | HansaBioMed, Linkoping University |
| NCT02966171 | Phase 1 | Jan 1, 2017 | Hutchison MediPharma |
| NCT02854059 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | HansaBioMed, University of London |
| NCT02790437 | Phase 2 | Jun 1, 2016 | HansaBioMed |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HansaBioMed | For profit | 17 | 13 | 3 | 2013 |
| Hutchison MediPharma | For profit | 5 | 5 | 2 | 2017 |
| Uppsala University | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Genethon | For profit | 1 | 1 | 1 | 2024 |
| Institut d'Investigacions Biomèdiques August Pi i Sunyer | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Linkoping University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Lund University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2020 |
| Sarepta Therapeutics | For profit | 1 | 1 | 1 | 2024 |
| University of Barcelona | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2023 |
15 organizations
Page 1 / 1